Prise en charge de la neutropénie fébrile chez le patient cancéreux

FRERES, Pierre; GONNE, Elodie; COLLIGNON, Joëlle; GIOT, Jean-Baptiste; GENNIGENS, Christine; JERUSALEM, Guy

Download

Article (Scientific journals)

Prise en charge de la neutropénie fébrile chez le patient cancéreux

FRERES, Pierre; GONNE, Elodie; COLLIGNON, Joëlle et al.

2015 • In Revue Médicale de Liège, 70 (4), p. 195-200

Peer reviewed

Permalink
https://hdl.handle.net/2268/184322

PubMed
26054171

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Prise en charge de la neutropénie fébrile chez le patient cancéreux.pdf

Publisher postprint (269.02 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

oncologie; neutropénie fébrile; cancer; chimiothérapie; oncology; febrile neutropenia; chemotherapy

Abstract :

[fr] Les cancers sont de plus en plus fréquents et leurs traitements de plus en plus agressifs. En conséquence, médecins généralistes, urgentistes, hématologues et oncologues se trouvent régulièrement confrontés à un effet secondaire sévère des traitements cytotoxiques, le neutropénie fébrile (NF). La NF est une complication gravissime de la chimiothérapie, car elle peut être rapidement mortelle et provoque un arrêt temporaire, voire définitif, des traitements. Dans cet article, nous résumons les dernières recommandations quant à la prise en charge thérapeutique des patients présentant une NF sous traitements anti-cancéreux.

Disciplines :

Oncology

Author, co-author :

FRERES, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

GONNE, Elodie ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

COLLIGNON, Joëlle ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

GIOT, Jean-Baptiste ; Centre Hospitalier Universitaire de Liège - CHU > Maladies infectieuses et médecine interne générale

GENNIGENS, Christine ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Language :

French

Title :

Prise en charge de la neutropénie fébrile chez le patient cancéreux

Publication date :

2015

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

195-200

Peer reviewed :

Peer reviewed

Available on ORBi :

since 24 July 2015

Statistics

Number of views

585 (27 by ULiège)

Number of downloads

2736 (20 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

De Naurois J, Novitzky-Basso I, Gill MJ, et al. - Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol, 2010, 21, 252-256.
Freifeld AG, Bow EJ, Sepkowitz KA, et al. - Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis, 2011, 52, 427-431.
Kuderer NM, Dale DC, Crawford J, et al. - Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 2006, 106, 2258-2266.
Klastersky J, Paesmans M, Rubenstein EB, et al. - The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients. J Clin Oncol, 2000, 18, 3038-3051.
Repetto L. - Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol, 2003, 1, 18-24.
Averbuch D, Orasch C, Cordonnier C, et al. - European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica, 2013, 98, 1826-1835.
Lyman GH, Dale DC, Friedberg J, et al. - Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol, 2004, 22, 4302-4311.
Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al. - A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma, 2000, 37, 351-360.
Lyman GH, Lyman CH, Agboola O. - Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005, 10, 427-437.
Scott S. - Identification of cancer patients at high risk of febrile neutropenia. Am J Health Syst Pharm, 2002, 59, S16-19.
Pizzo PA. - Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med, 1993, 328, 1323-1332.
Sipsas N V, Bodey G P, Kontoyiannis DP. - Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer, 2005, 103, 1103-1113.
Zhang Q, Raoof M, Chen Y, et al. - Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature, 2010, 464, 104-107.
Walsh TJ, Shoham S, Petraitiene R, et al. - Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol, 2004, 42, 4744-4748.
Vidal L, Paul M, Ben Dor I, et al. - Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother, 2004, 54, 29-37.
Teuffel O, Amir E, Alibhai S, et al. - Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. Br J Cancer, 2011, 104, 1377-1383.
Kern W V, Marchetti O, Drgona L, et al. - Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy-EORTC infectious diseases group trial X V. J Clin Oncol, 2013, 31, 1149-1156.
Gaieski DF, Mikkelsen ME, Band RA, et al. - Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med, 2010, 38, 1045-1053.
Furno P, Bucaneve G, Del Favero A. - Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infec Dis, 2002, 2, 231-242.
Hentrich M, Schalk E, Schmidt-Hieber M, et al. - Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. Ann Oncol, 2014, 30, 936-947.
Raad I, Kassar R, Ghannam D, et al. - Management of the catheter in documented catheter-related coagulasenegative staphylococcal bacteremia: remove or retain? Clin Infect Dis, 2009, 49, 1187-1194.
Schiffer CA, Mangu PB, Wade JC, et al. - Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2013, 31, 1357-1370.
Kovacs JA, Masur H. - Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA, 2009, 301, 2578-2585.
Ader F, Nseir S, Guery B, Tillie-Leblond I. - Aspergillose pulmonaire aiguë invasive et pathologies pulmonaires chroniques. Rev Mal Respir, 2005, 23, 11-20.
Cornely OA, Bassetti M, Calandra T, et al. - ESCMID^∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect, 2012, 18, 19-37.
Mousset S, Buchheidt D, Heinz W, et al. - Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol, 2013, 93, 13-32.
Dompeling EC, Donnelly J P, Deresinski SC, et al. - Early identification of neutropenic patients at risk of gram-positive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer, 1995, 32, 1332-1339.
Schmutzhard E, Williams KJ, Vukmirovits G, et al. - A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. J Antimicrob Chemother, 1995, 36, 85-97.
Wood A, Quagliarello VJ. - Treatment of bacterial meningitis. N Engl J Med, 1997, 336, 196-204.
Crawford J, Caserta C, Roila F. - Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol, 2010, 21, 248-251.
Smith TJ, Khatcheressian J, Lyman GH, et al. - 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol, 2006, 24, 3187-3205.